ADMA Gains 13.8% in Three Months: More Upside Potential for 2026?

Core Insights - ADMA Biologics' shares have increased by 13.8% over the past three months, outperforming the industry growth of 9% and the S&P 500 [1][8] - The stock's recovery is attributed to strong demand for its product Asceniv and a positive outlook for 2026 [4][19] Company Performance - ADMA Biologics specializes in plasma-derived biologics aimed at treating immune deficiencies and preventing certain infectious diseases [5][6] - The company's revenue is driven by three FDA-approved products: Bivigam, Asceniv, and Nabi-HB [5] - Asceniv, the lead product, is a plasma-derived IVIG that contains polyclonal antibodies to combat infections [6][7] Growth Drivers - Utilization of Asceniv has accelerated due to increased prescriber adoption, payer access, and confidence in product availability [8][9] - ADMA divested three plasma collection centers for $12 million and entered long-term plasma supply agreements, enhancing its sourcing model [9][10] - The company has successfully implemented yield-enhanced production, which is expected to improve gross margins starting in 2026 [10][11] Financial Outlook - ADMA raised its 2026 revenue forecast to approximately $635 million from $630 million, with adjusted EBITDA guidance increased to about $360 million [13] - Management projects revenues of approximately $775 million in 2027 and over $1.1 billion by fiscal 2029 [14] - The company's shares currently trade at a price/sales ratio of 7.96x, significantly higher than the industry average of 2.07x [15] Market Position - ADMA competes with Takeda and Grifols in the U.S. plasma-derived products market and is well-positioned for growth due to increasing demand for Asceniv [19]